SCHEDULE: Opaleye Management Discloses 8.59% Stake in Q32 Bio
Beneficial Ownership Filing
Opaleye Management Inc., Opaleye L.P., and James Silverman have jointly filed a Schedule 13G, reporting beneficial ownership of 1,256,228 shares, representing 8.59% of Q32 Bio Inc.'s common stock.
Summary
- Opaleye Management Inc., Opaleye L.P., and James Silverman have filed an amendment to their Schedule 13G filing.
- They collectively beneficially own 1,256,228 shares of Q32 Bio Inc. common stock.
- This ownership stake represents 8.59% of the company's outstanding common stock.
- The filing is based on 14,629,463 shares of Common Stock outstanding as of March 1, 2026, as reported by Q32 Bio Inc. in its Annual Report on Form 10-K filed on March 10, 2026.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing, as it is a routine disclosure of beneficial ownership and does not contain new operational or financial performance information.
Positives
- Significant ownership stake of 8.59% in Q32 Bio Inc. by Opaleye entities and James Silverman.
- The filing indicates a clear and disclosed position in the company.
Future Outlook
This filing does not contain forward-looking statements or guidance from the company. It is a disclosure of beneficial ownership.
Industry Context
StockSavvy.ai notes that Schedule 13G filings are common for institutional investors and significant shareholders to disclose their holdings. This filing indicates a notable stake by Opaleye entities in Q32 Bio Inc., a biotechnology company.
Stakeholder Impact
- Shareholders: The disclosure of a significant stake by Opaleye may be viewed positively by other shareholders, indicating confidence from an institutional investor. It also provides transparency regarding ownership structure.
- Management: The filing provides management with information on significant beneficial owners, which is a standard part of corporate governance.
Key Dates
| Date | Description |
|---|---|
| 03/01/2026 | Date as of which Q32 Bio Inc. had 14,629,463 shares of Common Stock outstanding. |
| 03/10/2026 | Date Q32 Bio Inc. filed its Annual Report on Form 10-K. |
| 05/06/2026 | Date of the Schedule 13G filing and the Joint Filing Agreement. |
Keywords
Q32 Bio Inc., Schedule 13G, Opaleye Management Inc., Opaleye L.P., James Silverman, Beneficial Ownership, SEC Filing, Common Stock, Investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.